BRIGHT-DATA
12.9.2022 15:23:36 CEST | Business Wire | Press release
Bright Data, the industry-leading web data platform, has today announced the acquisition of eCommerce insights provider Market Beyond. With this acquisition, Bright Data adds digital shelf analytics to its already comprehensive data offerings, introducing its new division – Bright Insights.
Market Beyond’s team will join Bright Data’s 400+-strong team, where they will lead the newly established Bright Insights division. This dedicated team will roll out Bright Insights to the company’s enterprise retail customer base with plans to expand in the future to further domains.
Through Bright Insights, leading retail brands, marketplaces and manufacturers will now be able to gain quality, reliable web data as well as critical business insights from one place. This will allow prominent brands to create strategies based on quality-driven data insights and, in turn, optimize and advance their business performance.
Since launching in Tel Aviv, Israel, in 2016, Market Beyond has worked with large manufacturers and brands within the eCommerce sphere to provide an accurate picture of both their and their competitors’ market share in the eCommerce landscape. Market Beyond has grown significantly and now has a global footprint with a dedicated US focus, where its customer base includes multiple Fortune 500 brands, such as Home Depot, eBay, Overstock and many more.
“The acquisition of Market Beyond, and the subsequent launch of Bright Insights, will allow retail sphere leaders to seamlessly get the real-time web data they need as well as the actionable insights crucial for split-second decision-making,” said Bright Data CEO Or Lenchner. “Bright Data’s focus on innovating web data products supports thousands of customers around the world. The introduction of Bright Insights will take data analysis to the next level. We look forward to welcoming the Market Beyond team into Bright Data's expanding family, and we are excited about the positive impact this will have on the data industry,” concluded Lenchner.
“This partnership not only signals a new chapter for Market Beyond but affirms our commitment to providing market-leading data-driven insights to leading businesses around the world,” said Market Beyond CEO Yuval Yifrach. “Market Beyond’s capabilities complement Bright Data’s industry-first technology perfectly. This deal, as well as the launch of Bright Insights, will allow us to continue providing market intelligence to brands and retailers and extend our reach to new markets. We have been working closely with Bright Data’s technology for over two years and we look forward to continuing to work alongside the entire Bright Data team as we create Bright Insights and push the boundaries of what is possible within the data-driven analysis space.”
-ENDS-
About Market Beyond
Since its establishment in 2016, Market Beyond’s unique AI & Machine Learning technology has served the largest brands across the world, specifically the market-leading brands, Fortune 500 included, in the US. Today, Market Beyond provides its dozens of customers in the retail space with reliable and precise real-time market insights that directly impact their present landscape as well as future strategic steps.
About Bright Data
Bright Data is the industry-leading web data platform. Fortune 500 companies, academic institutions, and small businesses rely on Bright Data’s solutions to retrieve public web data in the most efficient, reliable, and flexible way so they can research, monitor, and train their systems and analyze data to run better strategies and inform decision-making.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005571/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom